Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.53
ABT's Cash to Debt is ranked lower than
72% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. ABT: 0.53 )
Ranked among companies with meaningful Cash to Debt only.
ABT' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.31 Max: 1.28
Current: 0.53
0.05
1.28
Equity to Asset 0.53
ABT's Equity to Asset is ranked lower than
64% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ABT: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
ABT' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.45 Max: 0.59
Current: 0.53
0.37
0.59
Interest Coverage 9.57
ABT's Interest Coverage is ranked lower than
77% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 73.78 vs. ABT: 9.57 )
Ranked among companies with meaningful Interest Coverage only.
ABT' s Interest Coverage Range Over the Past 10 Years
Min: 4.25  Med: 10.89 Max: 17.59
Current: 9.57
4.25
17.59
F-Score: 6
Z-Score: 3.49
M-Score: -2.48
WACC vs ROIC
12.35%
72.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 14.74
ABT's Operating margin (%) is ranked higher than
81% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. ABT: 14.74 )
Ranked among companies with meaningful Operating margin (%) only.
ABT' s Operating margin (%) Range Over the Past 10 Years
Min: 7.14  Med: 13.45 Max: 20.27
Current: 14.74
7.14
20.27
Net-margin (%) 6.61
ABT's Net-margin (%) is ranked higher than
67% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. ABT: 6.61 )
Ranked among companies with meaningful Net-margin (%) only.
ABT' s Net-margin (%) Range Over the Past 10 Years
Min: 6.61  Med: 15.23 Max: 31.3
Current: 6.61
6.61
31.3
ROE (%) 6.55
ABT's ROE (%) is ranked higher than
60% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. ABT: 6.55 )
Ranked among companies with meaningful ROE (%) only.
ABT' s ROE (%) Range Over the Past 10 Years
Min: 6.55  Med: 20.51 Max: 28.49
Current: 6.55
6.55
28.49
ROA (%) 3.39
ABT's ROA (%) is ranked higher than
62% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. ABT: 3.39 )
Ranked among companies with meaningful ROA (%) only.
ABT' s ROA (%) Range Over the Past 10 Years
Min: 3.39  Med: 8.77 Max: 12.12
Current: 3.39
3.39
12.12
ROC (Joel Greenblatt) (%) 19.88
ABT's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 3.44 vs. ABT: 19.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ABT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 0.81  Med: 33.92 Max: 65.75
Current: 19.88
0.81
65.75
Revenue Growth (3Y)(%) 4.20
ABT's Revenue Growth (3Y)(%) is ranked higher than
51% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. ABT: 4.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ABT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.9  Med: 6.7 Max: 13.7
Current: 4.2
-17.9
13.7
EBITDA Growth (3Y)(%) 20.90
ABT's EBITDA Growth (3Y)(%) is ranked higher than
76% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 4.00 vs. ABT: 20.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ABT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -34  Med: 7.4 Max: 31.6
Current: 20.9
-34
31.6
EPS Growth (3Y)(%) 125.50
ABT's EPS Growth (3Y)(%) is ranked higher than
96% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. ABT: 125.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ABT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -65.6  Med: 8.6 Max: 125.5
Current: 125.5
-65.6
125.5
» ABT's 10-Y Financials

Financials (Next Earnings Date: 2017-04-20)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ABT Guru Trades in Q4 2015

Robert Olstein 201,000 sh (+14.20%)
Ken Fisher 17,286 sh (+13.32%)
Murray Stahl 22,503 sh (+4.65%)
Diamond Hill Capital 8,621,765 sh (+2.82%)
Mario Gabelli 17,625 sh (unchged)
Jeff Auxier 78,922 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Tom Russo 85,400 sh (unchged)
Dodge & Cox 30,268 sh (unchged)
Robert Bruce 230,915 sh (unchged)
David Carlson 600,000 sh (unchged)
Spiros Segalas 9,871,440 sh (unchged)
John Hussman Sold Out
Jim Simons Sold Out
Pioneer Investments 1,212,972 sh (-0.02%)
Mairs and Power 318,918 sh (-0.13%)
PRIMECAP Management 16,643,039 sh (-0.21%)
John Buckingham 91,506 sh (-0.43%)
First Eagle Investment 6,671,344 sh (-2.26%)
Richard Pzena 4,861,129 sh (-6.31%)
George Soros 664,181 sh (-9.20%)
Jeremy Grantham 5,653,313 sh (-12.61%)
Vanguard Health Care Fund 6,027,260 sh (-13.14%)
Ray Dalio 38,857 sh (-52.88%)
Paul Tudor Jones 13,100 sh (-78.06%)
Joel Greenblatt 98,838 sh (-93.21%)
» More
Q1 2016

ABT Guru Trades in Q1 2016

Joel Greenblatt 861,862 sh (+771.99%)
Diamond Hill Capital 10,198,087 sh (+18.28%)
First Eagle Investment 7,507,515 sh (+12.53%)
Robert Olstein 220,000 sh (+9.45%)
Murray Stahl 22,778 sh (+1.22%)
PRIMECAP Management 16,812,839 sh (+1.02%)
Mairs and Power 319,391 sh (+0.15%)
Vanguard Health Care Fund 6,027,260 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Robert Bruce 230,915 sh (unchged)
David Carlson 600,000 sh (unchged)
Paul Tudor Jones Sold Out
Jeff Auxier 78,672 sh (-0.32%)
Pioneer Investments 1,201,725 sh (-0.93%)
Dodge & Cox 29,268 sh (-3.30%)
Richard Pzena 4,642,170 sh (-4.50%)
John Buckingham 87,087 sh (-4.83%)
Ken Fisher 15,413 sh (-10.84%)
Mario Gabelli 13,695 sh (-22.30%)
Jeremy Grantham 3,713,180 sh (-34.32%)
George Soros 419,181 sh (-36.89%)
Ray Dalio 11,400 sh (-70.66%)
Tom Russo 20,400 sh (-76.11%)
Spiros Segalas 9,668,976 sh (-2.05%)
» More
Q2 2016

ABT Guru Trades in Q2 2016

Manning & Napier Advisors, Inc 152,221 sh (New)
Stanley Druckenmiller 385,400 sh (New)
Paul Tudor Jones 26,300 sh (New)
Ray Dalio 104,100 sh (+813.16%)
Vanguard Health Care Fund 10,508,900 sh (+74.36%)
John Buckingham 133,574 sh (+53.38%)
Mairs and Power 406,484 sh (+27.27%)
Diamond Hill Capital 11,968,670 sh (+17.36%)
Jeremy Grantham 4,345,234 sh (+17.02%)
Richard Pzena 5,327,448 sh (+14.76%)
Murray Stahl 22,978 sh (+0.88%)
Jeff Auxier 78,672 sh (unchged)
Jeremy Grantham 173,800 sh (unchged)
Dodge & Cox 29,268 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Robert Olstein Sold Out
Mario Gabelli 13,685 sh (-0.07%)
PRIMECAP Management 16,478,409 sh (-1.99%)
Pioneer Investments 978,987 sh (-18.53%)
Tom Russo 16,400 sh (-19.61%)
Ken Fisher 12,387 sh (-19.63%)
George Soros 329,181 sh (-21.47%)
Westport Asset Management 145,000 sh (-27.50%)
David Carlson 420,000 sh (-30.00%)
First Eagle Investment 2,974,455 sh (-60.38%)
Joel Greenblatt 130,054 sh (-84.91%)
Spiros Segalas 7,490,086 sh (-22.53%)
» More
Q3 2016

ABT Guru Trades in Q3 2016

Jim Simons 657,300 sh (New)
Steven Cohen 606,700 sh (New)
Stanley Druckenmiller 1,068,000 sh (+177.11%)
Mairs and Power 1,089,562 sh (+168.05%)
Jeremy Grantham 4,510,348 sh (+3.80%)
Ken Fisher 12,435 sh (+0.39%)
Mario Gabelli 13,695 sh (+0.07%)
Vanguard Health Care Fund 10,508,900 sh (unchged)
David Carlson 420,000 sh (unchged)
Steven Cohen 200,000 sh (unchged)
Dodge & Cox 29,268 sh (unchged)
Tom Russo 16,400 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Joel Greenblatt Sold Out
Spiros Segalas Sold Out
Jeff Auxier 78,622 sh (-0.06%)
John Buckingham 133,239 sh (-0.25%)
Diamond Hill Capital 11,875,781 sh (-0.78%)
Murray Stahl 22,628 sh (-1.52%)
Manning & Napier Advisors, Inc 149,363 sh (-1.88%)
PRIMECAP Management 15,720,699 sh (-4.60%)
Richard Pzena 5,017,660 sh (-5.81%)
Pioneer Investments 908,362 sh (-7.21%)
George Soros 259,181 sh (-21.26%)
Paul Tudor Jones 16,600 sh (-36.88%)
Ray Dalio 62,000 sh (-40.44%)
First Eagle Investment 1,271,914 sh (-57.24%)
» More
» Details

Insider Trades

Latest Guru Trades with ABT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NYSE:SYK, NYSE:BSX, NAS:ISRG, NYSE:STJ, NYSE:ZBH, NYSE:EW, OTCPK:SNNUF, NYSE:VAR, OTCPK:SONVY, NAS:ALGN, NYSE:TFX, OTCPK:CHEOY, NAS:ABMD, OTCPK:EKTAY, NAS:NUVA, NAS:IART, NAS:MASI, NAS:LIVN, NYSE:NVRO, NAS:WMGI » details
Traded in other countries:ABT.Argentina, ABTT34.Brazil, ABT.Chile, ABL.Germany, ABT.Mexico, ABT.Switzerland, ABT.UK,
Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.

Abbott Laboratories is an Illinois corporation, incorporated in 1900. The Company discovers, develops, manufactures and sells health care products. Its services are sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices and government agencies internationally. Its segments are Established Pharmaceutical Products, Nutritional Products, Diagnostic Products and Vascular Product. The Established Pharmaceutical Products is engaged in the International sales of various branded generic pharmaceutical products. Nutritional Products sells broad line of adult and pediatric nutritional products internationally. Diagnostic Products sells diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. This segment also includes Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions. Vascular Products sells coronary, endovascular, structural heart, vessel closure and other medical device products.

Guru Investment Theses on Abbott Laboratories

John Rogers Comments on Abbott Laboratories - Aug 18, 2016

In addition, cardiovascular muscle devices maker St. Jude Medical, Inc. (NYSE:STJ) popped +42.39% after a takeout offer. Specifically, Abbott Laboratories (NYSE:ABT) offered $ 46.75 in cash and 0.9 shares of Abbott stock for each share of St. Jude. The stock jumped more than 25% on the news of the offering.

From John Rogers (Trades, Portfolio)' second quarter 2016 market commentary.

Check out John Rogers latest stock trades

Mason Hawkins Comments on Abbott Laboratories - May 28, 2015

Abbott (ABT), a global healthcare company, reached our appraisal, resulting in a 120% return over our 4-year holding period. We are extremely appreciative of the value that CEO Miles White built for shareholders during our ownership.

From Mason Hawkins (Trades, Portfolio)’ Longleaf Partners Fund Q1 2015 Management Discussion.

Check out Mason Hawkins latest stock trades

Top Ranked Articles about Abbott Laboratories

Abbott Laboratories Announces Quarterly Dividend Health care company increased dividend by 1.9%
The board of Abbott Laboratories (NYSE:ABT) declared through PR Newswire Friday a dividend increase for the last quarter of the year. Read more...
Abbott Laboratories CEO Buys Stock in Company Insider invests in 369,950 shares in 5 separate transactions
Miles White (Insider Trades), CEO and chairman of Abbott Laboratories (ABT), purchased 369,950 shares in the company in five transations on Nov. 10. The per share price ranged from $40.45 to $40.67. Read more...
Abbott Labs: Absorb Heart Stent Approved in Japan The bioresorbable stent was approved in the US in July
Japanese patients affected by ischemic heart disease can finally be treated with Abbott's Absorb bioresorbable heart stent. Read more...
Weekly Top Insider Buys Highlight for Week of November 4 Largest Insider Buys for Abbott Laboratories, BlackRock Inc., Newell Brands Inc. and Williams Companies Inc.
Abbott Laboratories (NYSE:ABT): Director Sally E. Blount bought 5,100 shares Read more...
Alere's Shareholders Approve Merger With Abbott Seventy-seven percent voted 'yes'
Last Friday, 77% of Alere Inc. (NYSE:ALR)'s shareholders approved a merger with Abbott Laboratories (NYSE:ABT). Read more...
Abbott, St. Jude Medical: Agreement Reached in Sale of Vascular Closure Products toTerumo Sale agreement reached with Terumo Corp
Abbott Laboratories (NYSE:ABT) and St. Jude Medical Inc. (NYSE:STJ) agreed to sell St. Jude Medical's Angio-Seal and Femoseal, vascular closure products, and Abbott's Vado Steerable Sheath, a heart catheter, to Terumo Corp (TSE:4543) for a consideration of approximately $1.12 billion. Read more...
Abbott Releases 3rd Quarter Results The company reported revenue of $5.3 billion, nutrition segment down 2.0%
Today, Abbott Laboratories (NYSE:ABT) released its third quarter results. The U.S.-based international health care company reported a revenue of $5.3 billion (+2.9% year-over-year), beating analysts' expectations by $10 million and reported adjusted diluted earnings-per-share from continuing operations of 59 cents (+9.3% year-over-year), beating analysts' expectations by one cent. Read more...
Abbott Receives FDA Approval for Freestyle Libre The device lowers costs, maintenance and time compared to other professional CGM systems
On Sept. 23, Abbott (NYSE:ABTreceived approval from the Food and Drug Administration for the Freestyle Libre pro flash glucose monitoring system, a “professional continuous glucose monitoring (cgm) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes”(FDA). Read more...
Medical Companies Offer Good Value Opportunities A discussion of Peter Lynch, his top-performing strategies and good health care companies
Due to the great financial crisis, most companies were undervalued based on their valuations. Based on backtesting results, the “Peter Lynch Growth with Lower Valuation” test portfolio took positions in Baxter International Inc. (NYSE:BAX) and Abbott Laboratories (NYSE:ABT), two medical companies that reached historically low price-earnings ratios. While these companies presented good value opportunities from 2007-2011, other medical companies provide better opportunities in 2016. Read more...
John Rogers Comments on Abbott Laboratories Guru stock highlight
In addition, cardiovascular muscle devices maker St. Jude Medical, Inc. (NYSE:STJ) popped +42.39% after a takeout offer. Specifically, Abbott Laboratories (NYSE:ABT) offered $ 46.75 in cash and 0.9 shares of Abbott stock for each share of St. Jude. The stock jumped more than 25% on the news of the offering. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 43.47
ABT's P/E(ttm) is ranked lower than
69% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.16 vs. ABT: 43.47 )
Ranked among companies with meaningful P/E(ttm) only.
ABT' s P/E(ttm) Range Over the Past 10 Years
Min: 5.78  Med: 10.41 Max: 47.22
Current: 43.47
5.78
47.22
Forward P/E 15.85
ABT's Forward P/E is ranked higher than
83% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 21.74 vs. ABT: 15.85 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 59.84
ABT's PE(NRI) is ranked lower than
78% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.53 vs. ABT: 59.84 )
Ranked among companies with meaningful PE(NRI) only.
ABT' s PE(NRI) Range Over the Past 10 Years
Min: 5.93  Med: 20.83 Max: 250.57
Current: 59.84
5.93
250.57
Price/Owner Earnings (ttm) 1975.62
ABT's Price/Owner Earnings (ttm) is ranked lower than
99% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 30.39 vs. ABT: 1975.62 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ABT' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.51  Med: 9.59 Max: 2148.5
Current: 1975.62
4.51
2148.5
P/B 2.85
ABT's P/B is ranked higher than
55% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. ABT: 2.85 )
Ranked among companies with meaningful P/B only.
ABT' s P/B Range Over the Past 10 Years
Min: 1.39  Med: 2.25 Max: 3.34
Current: 2.85
1.39
3.34
P/S 2.88
ABT's P/S is ranked higher than
54% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.02 vs. ABT: 2.88 )
Ranked among companies with meaningful P/S only.
ABT' s P/S Range Over the Past 10 Years
Min: 0.96  Med: 1.73 Max: 6.27
Current: 2.88
0.96
6.27
PFCF 32.47
ABT's PFCF is ranked lower than
61% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.13 vs. ABT: 32.47 )
Ranked among companies with meaningful PFCF only.
ABT' s PFCF Range Over the Past 10 Years
Min: 4.38  Med: 8.92 Max: 40.16
Current: 32.47
4.38
40.16
POCF 20.50
ABT's POCF is ranked lower than
57% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 18.20 vs. ABT: 20.50 )
Ranked among companies with meaningful POCF only.
ABT' s POCF Range Over the Past 10 Years
Min: 3.82  Med: 6.7 Max: 23.88
Current: 20.5
3.82
23.88
EV-to-EBIT 36.86
ABT's EV-to-EBIT is ranked lower than
73% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.46 vs. ABT: 36.86 )
Ranked among companies with meaningful EV-to-EBIT only.
ABT' s EV-to-EBIT Range Over the Past 10 Years
Min: -214.2  Med: 14.85 Max: 5414.8
Current: 36.86
-214.2
5414.8
EV-to-EBITDA 20.20
ABT's EV-to-EBITDA is ranked lower than
61% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 16.23 vs. ABT: 20.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 10.6 Max: 28.4
Current: 20.2
4.3
28.4
Shiller P/E 14.65
ABT's Shiller P/E is ranked higher than
92% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 46.10 vs. ABT: 14.65 )
Ranked among companies with meaningful Shiller P/E only.
ABT' s Shiller P/E Range Over the Past 10 Years
Min: 9  Med: 12.76 Max: 17.98
Current: 14.65
9
17.98
Current Ratio 1.56
ABT's Current Ratio is ranked lower than
76% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. ABT: 1.56 )
Ranked among companies with meaningful Current Ratio only.
ABT' s Current Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.4 Max: 2.36
Current: 1.56
0.75
2.36
Quick Ratio 1.25
ABT's Quick Ratio is ranked lower than
69% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. ABT: 1.25 )
Ranked among companies with meaningful Quick Ratio only.
ABT' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 1.13 Max: 2.07
Current: 1.25
0.55
2.07
Days Inventory 110.05
ABT's Days Inventory is ranked higher than
61% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 134.83 vs. ABT: 110.05 )
Ranked among companies with meaningful Days Inventory only.
ABT' s Days Inventory Range Over the Past 10 Years
Min: 80.31  Med: 102.55 Max: 145.14
Current: 110.05
80.31
145.14
Days Sales Outstanding 58.52
ABT's Days Sales Outstanding is ranked higher than
63% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. ABT: 58.52 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.52  Med: 71.85 Max: 145.87
Current: 58.52
58.52
145.87
Days Payable 43.02
ABT's Days Payable is ranked lower than
62% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. ABT: 43.02 )
Ranked among companies with meaningful Days Payable only.
ABT' s Days Payable Range Over the Past 10 Years
Min: 35.38  Med: 41.44 Max: 73.71
Current: 43.02
35.38
73.71

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.64
ABT's Dividend Yield is ranked higher than
80% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. ABT: 2.64 )
Ranked among companies with meaningful Dividend Yield only.
ABT' s Dividend Yield Range Over the Past 10 Years
Min: 1.41  Med: 5 Max: 7.9
Current: 2.64
1.41
7.9
Dividend Payout 1.55
ABT's Dividend Payout is ranked higher than
51% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 0.39 vs. ABT: 1.55 )
Ranked among companies with meaningful Dividend Payout only.
ABT' s Dividend Payout Range Over the Past 10 Years
Min: 0.34  Med: 0.5 Max: 6.5
Current: 1.55
0.34
6.5
Dividend Growth (3y) -21.80
ABT's Dividend Growth (3y) is ranked lower than
89% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. ABT: -21.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
ABT' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -31.2  Med: 9 Max: 12.4
Current: -21.8
-31.2
12.4
Forward Dividend Yield 2.69
ABT's Forward Dividend Yield is ranked higher than
79% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 1.77 vs. ABT: 2.69 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.05
ABT's Yield on cost (5-Year) is ranked lower than
68% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. ABT: 1.05 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ABT' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.56  Med: 1.98 Max: 3.13
Current: 1.05
0.56
3.13
3-Year Average Share Buyback Ratio 2.20
ABT's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. ABT: 2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: -0.1 Max: 2.2
Current: 2.2
-0.8
2.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.96
ABT's Price/Tangible Book is ranked lower than
69% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 4.06 vs. ABT: 6.96 )
Ranked among companies with meaningful Price/Tangible Book only.
ABT' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.12  Med: 9.34 Max: 466.55
Current: 6.96
3.12
466.55
Price/Projected FCF 1.03
ABT's Price/Projected FCF is ranked higher than
81% of the 124 Companies
in the Global Medical Devices industry.

( Industry Median: 1.97 vs. ABT: 1.03 )
Ranked among companies with meaningful Price/Projected FCF only.
ABT' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.36  Med: 0.82 Max: 1.93
Current: 1.03
0.36
1.93
Price/Median PS Value 1.63
ABT's Price/Median PS Value is ranked lower than
83% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. ABT: 1.63 )
Ranked among companies with meaningful Price/Median PS Value only.
ABT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.58  Med: 1.12 Max: 3.49
Current: 1.63
0.58
3.49
Price/Graham Number 4.29
ABT's Price/Graham Number is ranked lower than
76% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 2.31 vs. ABT: 4.29 )
Ranked among companies with meaningful Price/Graham Number only.
ABT' s Price/Graham Number Range Over the Past 10 Years
Min: 1.18  Med: 2.4 Max: 20.86
Current: 4.29
1.18
20.86
Earnings Yield (Greenblatt) (%) 2.70
ABT's Earnings Yield (Greenblatt) (%) is ranked higher than
62% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. ABT: 2.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ABT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 6.4 Max: 18.5
Current: 2.7
0.1
18.5
Forward Rate of Return (Yacktman) (%) 10.27
ABT's Forward Rate of Return (Yacktman) (%) is ranked higher than
55% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 9.23 vs. ABT: 10.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ABT' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -18.7  Med: 12.85 Max: 32.3
Current: 10.27
-18.7
32.3

More Statistics

Revenue (TTM) (Mil) $20,708
EPS (TTM) $ 0.91
Beta1.55
Short Percentage of Float5.24%
52-Week Range $36.00 - 46.22
Shares Outstanding (Mil)1,472.31

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 20,921 23,470 22,731 23,984
EPS ($) 2.21 2.41 2.66 2.80
EPS w/o NRI ($) 2.21 2.41 2.66 2.80
EPS Growth Rate
(3Y to 5Y Estimate)
8.08%
Dividends Per Share ($) 1.02 1.08 1.22
» More Articles for ABT

Headlines

Articles On GuruFocus.com
Abbott's i-STAT Alinity Received CE Mark Nov 30 2016 
Medtronic Misses 2nd Quarter Revenue Expectations Nov 27 2016 
Abbott: $15 Billion Available From Notes Nov 25 2016 
Weak Outlook on Mylan Nov 18 2016 
Abbott Laboratories CEO Buys Stock in Company Nov 15 2016 
Abbott Labs: Absorb Heart Stent Approved in Japan Nov 07 2016 
Weekly Top Insider Buys Highlight for Week of November 4 Nov 05 2016 
Dividend Aristocrats in Focus Part 29: Abbott Laboratories Nov 03 2016 
Dividend Aristocrats in Focus Part 28: AbbVie Nov 03 2016 
AbbVie Reports 3rd Quarter Results Nov 01 2016 

More From Other Websites
A Deep Dive into the Developments at Alere Dec 09 2016
ABBOTT LABORATORIES Files SEC form 8-K, Change in Directors or Principal Officers Dec 09 2016
Why Abbott Laboratories Seeks to Terminate the Alere Acquisition Dec 09 2016
Abbott Laboratories Announces Quarterly Dividend Dec 09 2016
A Brief Recap of the Abbott–Alere Deal Developments Dec 09 2016
10:26 am Abbott Labs raises quarterly dividend to $0.265/share from $0.26/share Dec 09 2016
Abbott Raising Quarterly Dividend for 45th Straight Year Dec 09 2016
Asian stocks advance ahead of ECB decision Dec 07 2016
Abbott sues Waltham's Alere to end $5.8 billion buyout Dec 07 2016
Abbott wants out of $5.8 billion Alere deal Dec 07 2016
Abbott seeks to end buyout deal for Alere Dec 07 2016
[$$] Abbott Seeks to Terminate Alere Deal Dec 07 2016
Alere Issues Statement Regarding Abbott Lawsuit Dec 07 2016
Abbott seeks to end buyout deal for Alere Dec 07 2016
Abbott Looks to Kill Alere Deal Dec 07 2016
Abbott Seeks To Terminate Alere Acquisition: 'Not The Company We Agreed To Buy' Dec 07 2016
Abbott seeks to abort planned acquisition of Alere Dec 07 2016
Abbott seeks to terminate Alere acquisition Dec 07 2016
Abbott Files Suit to Terminate $5.8 Billion Alere Purchase Dec 07 2016
Abbott Seeks to Terminate Alere Acquisition Dec 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)